IPP Bureau
Lupin launches posaconazole delayed-release tablets
By IPP Bureau - February 18, 2021
posaconazole delayed-release tablets 100 mg are the generic equivalent of Noxafil.
Steady quarter with margin improvement for Glenmark: ICICI Securities
By IPP Bureau - February 17, 2021
India business grew 11.8% YoY vs mid-single digit industry growth.
Glenmark Q3 FY21 net profit up 30% at Rs 248 Cr
By IPP Bureau - February 15, 2021
The jump in profit is due to the better performance of the API business.
Steady performance; for Alkem Laboratories: ICICI Securities
By IPP Bureau - February 13, 2021
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
Jubilant Pharmova recovers: ICICI Securities
By IPP Bureau - February 13, 2021
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
Approval accorded under PLI Scheme for domestic manufacturing of medical devices
By IPP Bureau - February 12, 2021
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
Glenmark receives ANDA approval for Clindamycin Phosphate Gel
By IPP Bureau - February 12, 2021
According to IQVIA sales data for the 12 month period ending December 2020, the Cleocin T Gel, 1% market achieved annual sales of approximately $73.8 million.
LupinLife Launches ayurvedic energy supplement
By IPP Bureau - February 12, 2021
Be One is a 100% Ayurvedic health and wellness supplement.
.jpg "ICN to organise E-conference on India's Pharma Industry Outlook on Feb 12")
ICN to organise E-conference on India's Pharma Industry Outlook on Feb 12
By IPP Bureau - February 11, 2021
Indian Chemical News, an online news media covering Pharma, Chemical and Petrochemical sector is organizing an E-conference on “India's Pharma Industry Outlook 2021” on 12th February, 2021 from 3:00 PM – 4:30 PM.
Indian Pharma market to grow to US$ 130 bn by 2030: Gowda
By IPP Bureau - February 11, 2021
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
SMS Pharmaceuticals Q3FY21 consolidated PAT up to Rs. 21.39 Cr
By IPP Bureau - February 11, 2021
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
Sun Pharma Advanced Research Q3FY21 loss at Rs. 67.62 crore
By IPP Bureau - February 11, 2021
The company posted net loss of Rs. 55.51 crores for the period ended December 31, 2019.
J B Chemicals & Pharmaceuticals Q3FY 21 consolidated PAT up at Rs. 151.66 Cr
By IPP Bureau - February 11, 2021
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
Lupin receives approval for tavaborole topical solution
By IPP Bureau - February 10, 2021
Tavaborole Topical Solution, 5%, is an oxaborole antifungal.
Jubilant Pharmova Q3FY21 consolidated PAT at Rs. 309.93 Cr
By IPP Bureau - February 08, 2021
The company posted net profit of Rs.203.38 crores for the period ended December 31, 2019.
